Shire Files Marketing Application For Lifitegrast In Europe
Zacks Investment Research | Aug 16, 2017 05:18AM ET
Shire plc (NASDAQ:SHPG) announced that it has submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe. In fact, the application has been validated by the UK as the Reference Member State, involved in the Decentralized Procedure (DCP).
If approved, lifitegrast will be the first and only treatment among a new class of drugs. Consequently, it will give a significant boost to Shire’s efforts to build an ophthalmology unit. Notably, the MAA for the drug was supported by data from five clinical trials, including 2,500 patients.
Shares of the company have declined 13.3% compared with the Zacks classified industry’s fall of 2.4% on a year-to-date basis.
It is to be noted that Lifitegras was launched in August 2016 in the U.S. under the brand name Xiidra. In fact, Shire received a major boost when the FDA approved its Xiidra 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease (DED) in adults.
Per the company, Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition. Approximately 16 million adults in the U.S. are diagnosed with dry eye disease, underscoring significant need for treatments in this field. Xiidra also strongly competes with Allergan plc’s (NYSE:AGN) eye care drug Restasis.
Meanwhile, the company has a deep pipeline in ophthalmology comprising early-, mid- and late-stage candidates gained through organic growth and strategic acquisitions. Also, it remains committed to continued innovation in ophthalmics, where there are opportunities to address unmet need, and improve the lives of patients.
Zacks Rank & Stocks to Consider
Shire currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in health care sector include Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Sanofi (NYSE:SNY) . While Alexion sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see .
Alexion Pharmaceuticals’ earnings per share estimates have moved up from $4.55 to $4.77 for 2017 and from $5.49 to $6.43 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 12.26%. The share price of the company has increased 10.6% year to date.
Get The News You Want
Sanofi’s earnings per share estimates have increased from $3.20 to $3.31 for 2017 and from $3.36 to $3.38 for 2018 over last 30 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18.3% year to date.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.